Chemicals & Small Molecules

Tidutamab (XmAb-18087) is a humanized, affinity-optimized bispecific antibody (bsAb) targeting the SSTR2 and CD3 domains to bind somatostatin receptor 2 (SSTR2) and T cells, respectively. Featuring a full Fc domain for extended serum half-life, it engages in the targeted elimination of SSTR2-positive tumor cells via redirected T cell-mediated cytotoxicity (RTcC) [1].

Tidutamab (XmAb-18087) is a humanized, affinity-optimized bispecific antibody (bsAb) targeting the SSTR2 and CD3 domains to bind somatostatin receptor 2 (SSTR2) and T cells, respectively. Featuring a full Fc domain for extended serum half-life, it engages in the targeted elimination of SSTR2-positive tumor cells via redirected T cell-mediated cytotoxicity (RTcC) [1].

Sotatercept (ACE-011), a soluble activin receptor type IIA (ACVR2A) IgG Fc fusion protein, aims to rebalance growth-promoting and inhibiting signaling pathways by targeting activin and growth differentiation factors. This compound shows potential in treating pulmonary arterial hypertension, anemia, bone loss, erythropoiesis, and multiple myeloma (MM) osteolytic lesions [1] [2] [3] [4] [5].

Insulin efsitora alfa (LY-3209590) is a selective insulin receptor (IR) agonist, featuring a fusion protein that combines human IR agonists with the crystallizable (Fc) domain of human immunoglobulin G2 (IgG2), and has a molecular weight of 64.1 kDa. This compound is well tolerated and shows promise for diabetes management [1].

Ipafricept (OMP-54F28; FZD8-Fc) is a pioneering recombinant fusion protein composed of the extracellular segment of the human frizzled-8 receptor and the Fc fragment of human IgG1, targeting the Wnt ligand. It demonstrates activity in inhibiting solid tumors and is well tolerated [1].

Latikafusp (AMG 256), a bifunctional fusion protein, combines a PD-1-targeting antibody with an IL-21 mutein, facilitating IL-21 pathway stimulation in PD-1+ cells. It aims to enhance and sustain the functionality of cytotoxic and memory T cells, thereby inducing anti-tumor immunity. This compound shows promise for research in solid tumors [1] [2].

Nemvaleukin alfa (ALKS 4230), an IL-2 fusion protein, selectively targets intermediate-affinity IL-2R to activate NK and effector T cells, and is used in cancer research [1] [2] [3].

Recifercept (TA-46), a soluble, recombinant fibroblast growth factor receptor 3 (FGFR3) molecule, serves as a decoy/ligand trap to diminish the binding of fibroblast growth factors to mutant FGFR3 receptors. Primarily, it is utilized in achondroplasia research [1].

Simlukafusp alfa (FAP-IL2v) is an immunocytokine consisting of an antibody targeting fibroblast activation protein α (FAPα) linked to a variant of IL-2 that specifically interacts with IL-2Rβγ. The compound is of the human IgG1 isotype [1].